Controlled trial of combinations of hydroxocobalamin-cystine and riboflavine-cystine, in Nigerian ataxic neuropathy.
Chronic cyanide intoxication of dietary origin and riboflavine deficiency are believed to be major aetiological factors in Nigerian tropical ataxic neuropathy. The results are presented of a double-blind controlled therapeutic trial of combinations of large doses of hydroxocobalamin and cystine as cyanide binding agents together with riboflavine or placebos in Nigerian patients suffering from the tropical ataxic neuropathy. No clinical benefit was demonstrable with any of the treatments.
D001259:Ataxia / Q000188:drug therapy* / Q000209:etiology; D003486:Cyanides / Q000506:poisoning; D003553:Cystine / Q000627:therapeutic use*; D003638:Deafness / Q000188:drug therapy* / Q000209:etiology; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D006879:Hydroxocobalamin / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009549:Nigeria; D009896:Optic Atrophy / Q000188:drug therapy* / Q000209:etiology; D010523:Peripheral Nervous System Diseases / Q000188:drug therapy* / Q000209:etiology; D010919:Placebos; D011041:Poisoning / Q000188:drug therapy; D012256:Riboflavin / Q000627:therapeutic use*; D012257:Riboflavin Deficiency / Q000150:complications / Q000188:drug therapy; D013577:Syndrome; D013861:Thiocyanates / Q000097:blood; D014805:Vitamin B 12 / Q000627:therapeutic use
D003486:Cyanides; D010919:Placebos; D013861:Thiocyanates; D003553:Cystine; D014805:Vitamin B 12; D006879:Hydroxocobalamin; D012256:Riboflavin